首页> 外文期刊>Korean Circulation Journal >Endocan and Non-Dipping Circadian Pattern in Newly Diagnosed Essential Hypertension
【24h】

Endocan and Non-Dipping Circadian Pattern in Newly Diagnosed Essential Hypertension

机译:新诊断的原发性高血压的Endocan和非浸入式昼夜节律模式

获取原文
           

摘要

Background and Objectives Non-dipper hypertension is frequently accompanied by endothelial dysfunction and activation. Previous studies suggested that endocan may be a novel endothelial dysfunction marker. This study aims to investigate the association between circadian blood pressure (BP) pattern and plasma endocan levels together with high-sensitivity C-reactive protein (hsCRP) in patients with newly diagnosed untreated hypertension. Subjects and Methods Twenty-four hour ambulatory blood pressure monitoring was recorded in 35 dipper, 35 non-dipper hypertensives and 35 healthy controls. Endocan levels were measured by enzyme-linked immunosorbent assay. Serum levels of hsCRP were also recorded. Results Despite similar daytime and 24-hour average BP values between dippers and non-dippers, statistically significant high nocturnal BP was accompanied by a non-dipping pattern (Systolic BP: 132±9 vs. 147±11 mmHg; Distolic BP: 80±7 vs. 91±9 mmHg, respectively, p Conclusion Elevated endocan levels were found in non-dipper groups. Endocan and hsCRP were found to be independently associated with a non-dipping pattern. We suggest that elevated levels of endocan in non-dipper hypertensive patients might be associated with a longer duration of exposure to high BP. These results point to the possible future role of endocan in selection of hypertensive patients at higher risk or target organ damage.
机译:背景与目的非北斗星高血压常伴有内皮功能障碍和激活。先前的研究表明内皮糖可能是一种新型的内皮功能障碍标志物。这项研究旨在调查新诊断为未经治疗的高血压患者的昼夜节律(BP)模式和血浆内皮糖水平以及高敏C反应蛋白(hsCRP)之间的关系。对象和方法在35个北斗七星,35个非北斗星高血压和35个健康对照中记录了24小时动态血压监测。内切糖水平通过酶联免疫吸附测定法测量。还记录了血清hsCRP水平。结果尽管北斗星和非北斗星之间白天和24小时的平均BP值相近,但具有统计学意义的高夜间睡眠BP伴有非浸渍模式(收缩压:132±9 vs. 147±11 mmHg; Distolic BP:80±结论结论非浸剂组中内皮糖水平升高,Endocan和hsCRP与非浸剂形式独立相关,我们建议非浸剂中内皮糖水平升高。高血压患者可能与长时间暴露于高血压有关,这些结果表明,内皮糖可能在选择高风险或靶器官损害的高血压患者中发挥未来作用。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号